Skip to main content
SpringerLink
Log in

Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation

  • Original Article
  • Published:
Hepatology International Aims and scope Submit manuscript

Abstract

Background and aim

The effects of achieving sustained virological response (SVR) on recurrence and survival after curative treatment in patients with hepatitis virus C (HCV)-related hepatocellular carcinoma (HCC) is unclear. This study examined the influence of SVR achievement by interferon therapy before HCC occurrence on recurrence and survival.

Methods

This retrospective study included 518 patients who underwent surgical microwave ablation for initial HCV-related HCC between January 2001 and December 2015. Thirty-four patients had achieved SVR (SVR group) and 484 patients had not (control group). Clinical characteristics and long-term outcomes were compared between the two groups.

Results

Overall survival rates at 5 and 10 years after curative ablation were 95.8 and 80.4% in the SVR group, and 50.7 and 23.4% in the control, respectively (p < 0.0001). Recurrence-free survival rates at 5 and 10 years were 68.7 and 26.4% in the SVR group, and 24.5 and 7.8% in the control group, respectively (p < 0.0001). Multivariate analyses revealed that achieving SVR as an independent prognostic factor for both overall and recurrence-free survival. In the SVR group, the 5-year recurrence-free survival rates for patients with an interval of 5 years or fewer (n = 24) vs. more than 5 years (n = 10) between achieving SVR and curative ablation were 58.7 and 88.9%, respectively (p = 0.03).

Conclusions

Achieving SVR before HCC occurrence allowed a favorable clinical outcome after curative ablation in HCV-related HCC patients. Patients with HCC that occurred more than 5 years after achieving SVR had longer recurrence-free survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137–2150.

  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–1917.

  3. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009;44:102–107.

  4. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005;25:181–200.

  5. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998;351:1535–1539.

  6. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, Kobayashi M, Nakamura I, Murashima N, Kumada H, Kawanishi M. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124–1130.

  7. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, Nishioji K, Murakami Y, Kashima K. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999;30:653–659.

  8. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228–232.

  9. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543–1554.

  10. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Tsukamoto T, Shuto T, Takemura S, Yamamoto T, Ikebe T, Wakasa K, Shiomi S, Kinoshia H. Influence of previous interferon therapy on recurrence after resection of hepatitis. Jpn J Cancer Res 2001;92:59–66.

  11. Saito T, Chiba T, Suzuki E, Shinozaki M, Goto N, Kanogawa N, Motoyama T, Ogasawara S, Ooka Y, Tawada Y, Kanda T, Miyazaki M, Yokosuka O. Effect of previous interferon based therapy on recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Med Sci 2014;11:707–712.

  12. Miyatake H, Kobayashi Y, Iwasaki Y, Nakamura S, Ohnishi H, Kuwaki K, Toshomori J, Hagihara H, Nouso K, Yamamoto K. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci 2012;57:1092–1101.

  13. Kanogawa N, Ogasawara S, Chiba T, Saito T, Motoyama T, Suzuki E, Ooka Y, Tawada A, Kanda T, Mikami S, Azemoto R, Kaiho T, Shinozaki M, Ohtsuka M, Miyazaki M, Yokosuka O. Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor. J Gastroenterol Hepatol 2015;30:1197–1204.

  14. Conti F, Buonfiglioli F, Scuteri A, Crepsi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727–733.

  15. Takami Y, Ryu T, Wada Y, Saitsu H. Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases. J Hepatobiliary Pancreat Sci 2013;20:332–3341.

  16. Ryu T, Takami Y, Tsutsumi N, Tateishi M, Mikagi K, Wada Y, Saitsu H. Simultaneous microwave coagulo-necrotic therapy (MCN) and laparoscopic splenectomy for the treatment of hepatocellular carcinoma with cirrhotic hypersplenism. Surg Today 2017;47:548–554.

  17. Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H. Efficacy of surgical treatment using microwave coagulo-necrotic therapy for unresectable multiple colorectal liver metastases. OncoTargets Ther 2016;9:937–943.

  18. Takenaka K, Kawahara N, Yamamoto K, Kajiyama K, Maeda T, Itasaka H, Shirabe K, Nishizaki T, Yanaga K, Sugimachi K. Results of 280 liver resections for hepatocellular carcinoma. Arch Surg 1996;131:71–76.

  19. Kobayashi A, Miyagawa S, Miwa S, Nakata T. Prognostic impact of anatomical resection on early and late intrahepatic recurrence in patients with hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2008;15:515–521.

  20. Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T, Suzuki Y, Suzuki F, Tsubota A, Akuta N, Kumada H. Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis. J Gastroenterol 2003;38:865–876.

  21. Nagaoki Y, Aikata H, Nakano N, Shinohara F, Nakamura Y, Hatooka M, Morio K, Kan H, Fujino H, Kobayashi T, Fukuhara T, Masaki K, Ono A, Nakahara T, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Kawakami Y, Ochi H, Chayama K. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: a large-scale, long-term cohort study. J Gastroenterol Hepatol 2016;31:1009–1015.

  22. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009;49:658–664.

Download references

Funding

No funding was received for this study.

Author information

Authors and Affiliations

  1. Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, 1-8-1 Jigyohama Chuo-ku, Fukuoka, 810-8563, Japan

    Tomoki Ryu, Yuko Takami, Yoshiyuki Wada, Masaki Tateishi, Hajime Matsushima, Munehiro Yoshitomi, Kazuhiro Mikagi & Hideki Saitsu

Authors
  1. Tomoki Ryu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuko Takami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshiyuki Wada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaki Tateishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hajime Matsushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Munehiro Yoshitomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuhiro Mikagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hideki Saitsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study conception and design: TR, YT, and HS. Acquisition of data: TR, YW, MT, HM, MY, and KM. Analysis and interpretation of data: TR, YT, and HS. Drafting of manuscript: TR. Critical revision: YT, and HS.

Corresponding author

Correspondence to Tomoki Ryu.

Ethics declarations

Conflict of interest

Tomoki Ryu, Yuko Takami, Yoshiyuki Wada, Masaki Tateishi, Hajime Matsushima, Munehiro Yoshitomi, Kazuhiro Mikagi, and Hideki Saitsu declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ryu, T., Takami, Y., Wada, Y. et al. Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation. Hepatol Int 12, 149–157 (2018). https://doi.org/10.1007/s12072-018-9851-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-018-9851-4

Keywords

Search

Navigation